Bellevue Group AG Acquires 21,768 Shares of Phreesia, Inc. (NYSE:PHR)

Bellevue Group AG lifted its holdings in Phreesia, Inc. (NYSE:PHR) by 5.2% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 443,341 shares of the company’s stock after purchasing an additional 21,768 shares during the period. Bellevue Group AG’s holdings in Phreesia were worth $10,609,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Conestoga Capital Advisors LLC lifted its stake in shares of Phreesia by 1.0% in the 1st quarter. Conestoga Capital Advisors LLC now owns 78,085 shares of the company’s stock worth $1,869,000 after purchasing an additional 750 shares during the period. ProShare Advisors LLC raised its stake in Phreesia by 8.6% during the 1st quarter. ProShare Advisors LLC now owns 9,522 shares of the company’s stock worth $228,000 after acquiring an additional 751 shares during the period. Swiss National Bank raised its stake in Phreesia by 1.0% during the 1st quarter. Swiss National Bank now owns 104,300 shares of the company’s stock worth $2,496,000 after acquiring an additional 1,000 shares during the period. Essex Investment Management Co. LLC raised its stake in Phreesia by 1.9% during the 1st quarter. Essex Investment Management Co. LLC now owns 59,764 shares of the company’s stock worth $1,430,000 after acquiring an additional 1,102 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Phreesia by 11.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,757 shares of the company’s stock worth $295,000 after acquiring an additional 1,324 shares during the period. Institutional investors own 92.10% of the company’s stock.

Insider Activity at Phreesia

In related news, Director Mark Douglas Smith sold 7,000 shares of the firm’s stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $25.00, for a total value of $175,000.00. Following the completion of the transaction, the director now directly owns 30,653 shares of the company’s stock, valued at $766,325. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Phreesia news, CEO Chaim Indig sold 2,644 shares of Phreesia stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $23.74, for a total transaction of $62,768.56. Following the completion of the transaction, the chief executive officer now directly owns 1,219,361 shares of the company’s stock, valued at $28,947,630.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark Douglas Smith sold 7,000 shares of Phreesia stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $25.00, for a total transaction of $175,000.00. Following the transaction, the director now directly owns 30,653 shares of the company’s stock, valued at $766,325. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,506 shares of company stock valued at $375,299. 5.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on PHR shares. Stephens restated an “overweight” rating and set a $28.00 target price on shares of Phreesia in a research note on Friday, May 31st. Truist Financial restated a “buy” rating and set a $29.00 target price on shares of Phreesia in a research note on Monday, July 1st. Needham & Company LLC restated a “buy” rating and set a $29.00 target price on shares of Phreesia in a research note on Friday, May 31st. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a report on Friday, May 31st. Finally, KeyCorp cut their price objective on shares of Phreesia from $27.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.54.

Phreesia Price Performance

Shares of PHR stock traded up $0.35 on Friday, reaching $24.77. The company’s stock had a trading volume of 394,560 shares, compared to its average volume of 440,717. The stock’s fifty day simple moving average is $21.30 and its 200-day simple moving average is $23.12. Phreesia, Inc. has a 1 year low of $12.05 and a 1 year high of $32.11. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -11.41 and a beta of 0.93.

Phreesia (NYSE:PHR) last posted its earnings results on Thursday, May 30th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.16. Phreesia had a negative net margin of 31.87% and a negative return on equity of 46.89%. The firm had revenue of $101.20 million during the quarter, compared to analyst estimates of $100.94 million. During the same period last year, the firm posted ($0.70) earnings per share. Phreesia’s revenue for the quarter was up 20.8% compared to the same quarter last year. Analysts forecast that Phreesia, Inc. will post -1.16 earnings per share for the current fiscal year.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.